Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nektar TherapeuticsNASDAQ: NKTR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $39.13M rose 30.9% year over year, ahead of the +6.1% change in trailing-twelve-month research & development. Sequentially, it rose 9.7% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.

Context

  • Research & development amounted to 212.4% of revenue in FY2025, up 89.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +30.9% holds above the trailing-twelve-month pace of +6.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$39.13M+9.7% QoQ
Last fiscal yearDec 2025
$117.33M-3.0% YoY
LTMJun 2026
$131.77M+6.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.9%——
1 year-3.0%——
3-year CAGR-18.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
117.33M USD
Year-over-year change
-3.0%
4-year CAGR
-26.4%

Research & Development vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.1% is the 6th highest of 10, against a peer median of +11.4%.
  • Research & development amounts to 241.4% of revenue for NKTR, versus a peer median of 243.6%.
NKTR Competitors
Research & Development for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$497M USD+2.5%+22.0%424.8%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
XNCRXencor, Inc.LTM Jun 2026$255.77M USD+11.4%+6.3%243.6%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
NKTRNektar TherapeuticsLTM Jun 2026$131.77M USD+6.1%-18.7%241.4%
CHRSCoherus Oncology, Inc.LTM Mar 2026$102.32M USD+17.6%-19.3%218.2%
ANLAdlai Nortye Ltd.LTM Jun 2024$56.93M USD—-15.5%877.1%
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M USD+64.5%+11.3%—
CGENCompugen Ltd.LTM Mar 2026$23.92M USD-1.0%-9.4%32.9%
Peer median (excluding NKTR) —+11.4%+0.4%243.6%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.